Australija - engleski - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; maize starch; povidone; crospovidone; stearic acid; colloidal anhydrous silica - codalgin forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fludarabine phosphate, quantity: 50 mg - injection, powder for - excipient ingredients: mannitol; sodium hydroxide - treatment of b-cell chronic lymphocytic leukaemia

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - paracetamol; codeine phosphate - oral tablet - 500mg ; 8mg

Kenija - engleski - Pharmacy and Poisons Board

medisel kenya ltd p.o box 540-01000 thika - dihydroartemisinin and piperaquine phosphate - tablet - dihydroartemisinin 40mg and piperaquine phosphate… - antimalarial antiprotozoals: combinations of

Australija - engleski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin phosphate, quantity: 0 qs (equivalent: clindamycin, qty 150 mg/ml) - injection, solution - excipient ingredients: water for injections; benzyl alcohol; sodium hydroxide; disodium edetate; hydrochloric acid - indications as at 20 june 2005 : dalacin c phosphate is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. dalacin c phosphate is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin - allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes - serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection, all when given in conjunction with an antibiotic of appropriate gram

Australija - engleski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin phosphate, quantity: 0 qs (equivalent: clindamycin, qty 150 mg/ml) - injection, solution - excipient ingredients: disodium edetate; hydrochloric acid; water for injections; sodium hydroxide; benzyl alcohol - indications as at 20 june 2005 : dalacin c phosphate is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. dalacin c phosphate is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin - allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes - serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract) and infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection, all when given in conjunction with an antibiotic of appropriate g

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - tilmicosin phosphate - oral solution/suspension - tilmicosin phosphate antibiotic active 250.0 mg/ml - antibiotic & related - pigs | boar | gilt | piglet | sow | swine - actinobacillus pleuropneumoniae (haemoph | actinomyces pyogenes | mycoplasma hyopneumoniae | pasteurella multocida | fowl cholera | reduction of lung lesions | respiratory disease | swine enzootic pneumonia

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - tilmicosin phosphate - oral solution/suspension - tilmicosin phosphate antibiotic active 250.0 mg/ml - antibiotic & related - pigs | boar | gilt | piglet | sow | swine - actinobacillus pleuropneumoniae (haemoph | actinomyces pyogenes | mycoplasma hyopneumoniae | pasteurella multocida | fowl cholera | reduction of lung lesions | respiratory disease | swine enzootic pneumonia

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - tylosin as the phosphate - oral powder, pre-mix - tylosin as the phosphate antibiotic active 100.0 g/kg - antibiotic & related - cattle | pigs | poultry | poultry broilers (meat for human consum) | beef | boar | bos indicus | bos taurus | bovine | breeders - antibiotic - anti-infective | bacterial infection | ileitis | liver abscess | mineral and nutritional additive | necrotic enteritis | promote animal growth | abrasions | abscesses | acetonaemia | actinobacillosis | airsacculitis | amino acid supplement | amino acids | amoxycillin sensitive bacteria | antiseptic | associated with viral disease | avian mycoplasmas | blackhead | body odours | bone fragility | bone growth | bowed tendons | broad spectrum | burns | calcium supplement | cartilage strength | coccidiosis | coliform complex | conjunctivitis | copper deficiency | cowpox | cracks | crusts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | egg shell | endometritis | enteric diseases | enzootic pneumonia | fatty acid deficiency | fatty liver | feed conversion | feed efficiency | finishing | fungal infections | girth galls | glucose | gram negative organisms | gram positive organisms | grass tetany | growth promotion | growth rate | hepatotoxic drugs | hypocalcaemia | hypo

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

max health limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 4 mg/ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: disodium edetate nitrogen propylene glycol sodium hydroxide water for injection - dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid. when so supplemented, dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy; · relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available; · primary and secondary adrenocortical insufficiency.